Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
株式のランク #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
株価
$8.74
最終同期: 2026-08-28
時価総額
$699.74M
変化(1日)
-4.85%
変化(1年)
-2.29%
US
取引 BridgeBio Oncology Therapeutics Inc. (BBOT)

カテゴリー

BridgeBio Oncology Therapeutics Inc.(BBOT)の配当利回りの履歴
BridgeBio Oncology Therapeutics Inc.(銘柄コード: BBOT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
BridgeBio Oncology Therapeutics Inc.(BBOT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)